Geron

Geron is a startup based in the United States. Its most recent tracked round is Growth. Brouky classifies it under Healthcare & Life Sciences. Brouky records 2 investors associated with the company.

Geron is a late-stage clinical biopharmaceutical company developing and potentially commercializing the first-in-class telomerase inhibitor, imetelstat, for the treatment of hematologic myeloid malignancies such as lower-risk myelodysplastic syndromes and myelofibrosis.